Page 2 - Jeffrey Hackman News Today

Kforce names a new COO and CFO on Sept. 7, according to a filing with the US Securities and Exchange Commission. The former COO will be leaving the firm.

Kforce names a new COO and CFO on Sept. 7, according to a filing with the US Securities and Exchange Commission. The former COO will be leaving the firm.

Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass.,... -Today at 08:01 am- MarketScreener

Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies

WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve

By Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) said it completed a $4.1 million private placement of shares and warrants to existing stockholders. The company said it aims to develop new biologic medicines to improve patient access and convenience. Comera has entered into a registration rights agreement to register the resale of the […]

– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to...

We have people taking two or three different injectable drugs every other week.

Having patients give themselves injections, when possible, not only saves clinic time and expense, but also spares the patients a trip to the clinic, of course, and often a copay.

- Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company - - Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab),